Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
20 juil. 2020 16h15 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference
29 mai 2020 16h05 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
29 mai 2020 08h00 HE
|
Larimar Therapeutics, Inc.
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020- Company signed $80 million in private placement financing with biotechnology focused...
Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results
05 mars 2020 16h05 HE
|
Zafgen, Inc.
Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for...
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
18 déc. 2019 06h00 HE
|
Zafgen, Inc.; Chondrial Therapeutics
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1...
Zafgen Reports Third Quarter 2019 Financial Results
06 nov. 2019 16h01 HE
|
Zafgen, Inc.
Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019,...
Zafgen to Explore Strategic Alternatives
05 sept. 2019 07h00 HE
|
Zafgen, Inc.
BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Second Quarter 2019 Operating and Financial Results
08 août 2019 16h15 HE
|
Zafgen, Inc.
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study...
Zafgen to Present at the Wedbush PacGrow Healthcare Conference
06 août 2019 16h15 HE
|
Zafgen, Inc.
BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061
24 juil. 2019 16h15 HE
|
Zafgen, Inc.
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the...